Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals

Table 1 Subjects’ baseline characteristics

Characteristics	Overall (n = 68)	Child pugh A (n = 54)	Child pugh B (n = 14)	P value
Age (yr), mean ± SD	55 ± 8.6	55.2 ± 9.5	54.6 ± 5	0.8
Male, n (%)	52 (76.5)	43 (79.6)	9 (64.3)	0.2
White race, n (%)	66 (97.1)	53 (98.1)	13 (92.9)	0.3
HIV infection, n (%)	39 (57.4)	29 (53.7)	10 (71.4)	0.2
HBsAg positive, n (%)	1 (1.5)	1 (1.9)	0	-
History of HCC, n (%)	6 (8.8)	4 (7.4)	2 (14.3)	0.6
HCV treatment experienced, n (%)	43 (63.2)	33 (61.1)	10 (71.4)	0.5
Liver stiffness (kPa), median (IQR)	21.4 (15.9-34.4)	21.2 (15.6-33.1)	31.1 (17.8-54.3)	0.1
HCV genotype, n (%)				0.7
1a	23 (33.8)	18 (33.3)	5 (35.7)
1b	11 (16.2)	9 (16.7)	2 (14.3)
2	6 (8.8)	6 (11.1)	-
3	22 (32.4)	17 (31.5)	5 (35.7)
4	6 (8.8)	4 (7.4)	2 (14.3)
Weight (kg), mean ± SD	73 ± 14.1	73.2 ± 15.3	72.1 ± 8.5	0.7
Hb baseline (g/L), mean ± SD	143 ± 18	146 ± 16	129 ± 17	0.002
Bilirubin (mg/L), median (IQR)	9.5 (5.6-19)	4.7 (2.8-8.2)	7.7 (5.3-16)	< 0.001
Creatinine (mg/L), mean ± SD	8 ± 1.3	8.2 ± 1.5	7.5 ± 0.8	0.011
eGFR (mL/min per 1.73 m2), median (IQR)	101 (90-109)	99 (88-105)	102 (98-107)	0.3
HCV-RNA baseline (IU/mL)	933559 (25667-2128936)	1228876 (410822-2940050)	246455 (126308-712307)	0.007
1DAAs regimen, n (%)				0.2
SOF, n (%)	6 (8.8)	6 (11.1)	-
SOF + DCV, n (%)	29 (42.6)	21 (38.9)	8 (57.1)
SOF + SMP, n (%)	1 (1.5)	-	1 (7.1)
DCV + SMP, n (%)	4 (5.9)	3 (5.6)	1 (7.1)
SOF + LDV, n (%)	12 (17.6)	11 (20.4)	1 (7.1)
OBV/PTV/r + DSV, n (%)	12 (17.6)	9 (16.7)	3 (21.4)
OBV/PTV/r, n (%)	4 (5.9)	4 (7.4)	-

¹All regimens are intended in association with ribavirin. HCC: Hepatocellular carcinoma; eGFR: Estimated glomerular filtration rate; DAAs: Direct-acting antivirals; SOF: Sofosbuvir; DCV: Daclatasvir; SMP: Simeprevir; LDV: Ledipasvir; OBV: Ombitasvir; PTV: Paritaprevir; R: Ritonavir; DSV: Dasabuvir.